A Decision Framework Lean toward Contrave if: Eating is primarily driven by cravings, reward-seeking, or emotional triggers You have depression that might benefit from bupropion You strongly prefer oral medication You cannot take GLP-1 medications Insurance covers Contrave but not semaglutide Weight loss goals are more modest (5-10%) Lean toward semaglutide if: You want maximum weight loss (15%+) You have cardiovascular disease or high risk You have diabetes or prediabetes Your eating is driven by persistent hunger and difficulty feeling full You prefer weekly over daily medication You can afford it or have coverage Either might work if: You have mixed eating patterns No clear medical factor driving choice Both are accessible and affordable Moderate weight loss would meet your goals Discuss With Your Provider Bring these considerations to your healthcare provider: Your specific eating patterns and challenges Your complete medical history and current medications Your weight loss goals Your insurance coverage and budget Your preferences about administration Your provider can help weigh these factors against your specific health profile
%20receptor%20agonist)%202mg%20per%20week%20to%20tirzepatide%20(dual%20glucagon-like%20peptide-1%20(GLP-1)%20and%20glucose-dependent%20insulinotropic%20polypeptide%20(GIP)%20receptor%20agonist)%3F)
These co-agonists have been shown to reduce glucose levels and body weight in people with overweight/obesity and type 2 diabetes, with nausea and vomiting the most frequently detected side effects (reviewed in [80, 81])
Your Klinic provider will perform a thorough evaluation to ensure tirzepatide is suitable for your needs
Non-urgent GP consultation (within 24-48 hours) is appropriate for less severe but concerning symptoms, including persistent palpitations without associated chest pain or breathlessness, unexplained fatigue or exercise intolerance that develops after starting Ozempic, recurrent dizziness or light-headedness (particularly postural), or new-onset ankle swelling
When your body is carrying a significant inflammatory burden from gut permeability, chronic stress, environmental toxin accumulation, or years of metabolic dysfunction your cells read that inflammation as a danger signal
Customers can treat this as a melanocortin-pathway reference only